跳至主要内容
临床试验/EUCTR2005-005859-18-IT
EUCTR2005-005859-18-IT进行中(未招募)不适用

EFFECT OF MEMANTINE TREATMENT ON BRAIN FUNCTION AND MORPHOLOGICAL STRUCTURE IN PATIENTS WITH MODERATE TO SEVERE PATIENTS WITH ALZHEIMER S DISEASE A STRUCTURAL MR AND FMRI STUDY - ND

FONDAZIONE SANTA LUCIA0 个研究点开始时间: 2006年11月10日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - age at baseline at least 50 years; - MRI or TC tomography computerized done within 12 months before the recruitment in agree with the NINCDS-ADRDA criteria for probable AD; - AD patients with a MMSE score equal or higher than 10. - Moderate AD subjects in stable therapy with anticholinesterase inhibitors for at least 3 months; - drugs permitted at stable doses for at least 2 weeks before the recruitment antidepressive, anti-inflammatory, antiipertensive, antipsichotics atypical, vitamine E 1200 mg/day , anticoagulants, blue pills, diuretics, ipnotics.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - patients with B12 or folic acid clinically significative deficits; - patients with other diseases at time of baseline or not pharmacological corrected such as pulmonary, gastrointestinal, nephritic, cardiovascular; - patients with other psychiatric or central nervous system diseases, in excess of those ones necessary to diagnose probable AD; - patients with a score at Hachinski modified scale more than 4 Rosen WG, et al. 1980 .

研究者

相似试验